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ABSTRACT
Objective Ivabradine, a speciﬁc heart rate lowering
therapy, has been shown in a randomised placebo-
controlled study, Systolic HF Treatment with the If
Inhibitor Ivabradine Trial (SHIfT), to signiﬁcantly reduce
the composite end point of cardiovascular death and
hospitalisation for worsening heart failure (HF) in
patients with systolic HF who are in sinus rhythm and
with a heart rate ≥70 bpm, when added to optimised
medical therapy (HR: 0.82, 95% CI 0.75 to 0.90,
p<0.0001). We assessed the cost effectiveness of
ivabradine, from a UK National Health Service
perspective, based on the results of SHIfT.
Methods A Markov model estimated the cost
effectiveness of ivabradine compared with standard care
for two cohorts of patients with HF (heart rate ≥75 bpm
in line with the EU labelled indication; and heart rate
≥70 bpm in line with the SHIfT study population).
Modelled outcomes included death, hospitalisation,
quality of life and New York Heart Association class.
Total costs and quality adjusted life years (QALYs) for
ivabradine and standard care were estimated over a
lifetime horizon.
Results The incremental cost per additional QALY for
ivabradine plus standard care versus standard care has
been estimated as £8498 for heart rate ≥75 bpm and
£13 764 for heart rate ≥70 bpm. Ivabradine is expected
to have a 95% chance of being cost-effective in the EU
licensed population using the current National Institute
for Health and Care Excellence cost effectiveness
threshold of £20 000 per QALY. These results were
robust in sensitivity analyses.
Conclusions This economic evaluation suggests that
the use of ivabradine is likely to be cost-effective in
eligible patients with HF from a UK National Health
Service perspective.
INTRODUCTION
Heart failure (HF) is a clinical syndrome charac-
terised by the inability of the heart to pump
enough blood to meet the body’s demands.
Symptoms include dyspnoea and fatigue which may
limit exercise tolerance as well as ﬂuid retention
which may lead to peripheral oedema and pulmon-
ary congestion. The British Heart Foundation
(BHF) estimates that around 750 000 people in the
UK have HF and there are approximately 25 000
new cases each year. Prognosis from HF is poor
and the 5-year survival rate for patients with HF is
estimated to be only 58%.1–3
Epidemiological and clinical studies indicate that
a higher resting heart rate in sinus rhythm is asso-
ciated with increased morbidity and mortality in
the general population and in patients with cardio-
vascular (CV) disease. Heart rate reduction is asso-
ciated with improved outcomes in patients with
HF4 and some of the beneﬁcial effects of
β-blockade may be attributed to heart rate reduc-
tion.5 However, some patients cannot tolerate
target dosages of β-blockers and, when resting
heart rates remain elevated despite efforts to opti-
mise β-blocker dose, there is potential beneﬁt from
further heart rate reduction.
Ivabradine is a pure heart rate lowering therapy,
which acts by selective and speciﬁc inhibition of the
cardiac pacemaker current via the If channel. The
effect of using ivabradine to slow the heart rate in
patients with systolic HF, in addition to standard
care medications including β-blockade, has been
examined in a large, randomised, placebo-
controlled trial: Systolic HF Treatment with the If
Inhibitor Ivabradine Trial (SHIfT).
6 This trial
assessed 6505 patients with symptomatic HF
(New York Heart Association (NYHA) classes II to
IV), sinus rhythm, and a left ventricular EF ≤35%,
with a prior hospitalisation for HF within
12 months and a baseline resting heart rate
≥70 bpm despite optimised medical therapy.
Ivabradine therapy was associated with a signiﬁcant
reduction in the number of primary composite end
point events compared with standard care (CV
death or hospitalisation for worsening HF; HR:
0.82; 95% CI 0.75 to 0.90, p<0.0001). This result
was driven primarily by a reduction in HF hospita-
lisations (ﬁrst event worsening HF HR: 0.74; 95%
CI 0.66 to 0.83, p<0.0001) and HF death (HR:
0.74; 95% CI 0.58 to 0.94, p=0.014). There was
also a reduction in overall CV mortality (HF and
other CV mortality HR: 0.91; 95% CI 0.80 to
1.03, p=0.128), however, this result did not
achieve statistical signiﬁcance.
The ivabradine treatment effect was found to be
consistent across most patient subgroups but was
modiﬁed by baseline heart rate. In patients with a
heart rate ≥75 bpm, a signiﬁcant treatment effect
was also demonstrated on CV mortality (HR: 0.83;
95% CI 0.71 to 0.97, p=0.02) as well as all-cause
mortality (HR: 0.83; 95% CI 0.72 to 0.96).7
Standard care treatment patterns in SHIfT appeared
at least as good as clinical practice in the UK and
elsewhere in Europe,8 even though only 26% of
patients achieved the target dose β-blockade
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considered to represent gold standard β-blocker therapy in
patients with HF. While it is not expected that target dose
β-blockade can be achieved in all patients in clinical practice,
due to intolerance to therapy and contraindications to use, it is
recognised that β-blockade lowers resting heart rate and the
effect of ivabradine is modiﬁed by resting heart rate.
Adoption of new treatment is inﬂuenced by an assessment of
the relative efﬁcacy and safety of the treatment, and by whether
an intervention is likely to represent value for money, assessed
using economic evaluation which systematically compares the
costs and beneﬁts of a new therapy relative to existing care. A
cost effectiveness analysis was developed to compare ivabradine
plus standard care versus standard care alone using resource use
and clinical outcomes reported in SHIfT. The model has been
designed to be adapted to a population consistent with the
European licensed indication (heart rate ≥75 bpm). The model
also presents results for an average population which has been
optimised on β-blocker therapy according to current clinical
practice, as well as for a subgroup population treated with target
dose β-blockade given interest in the treatment effect of ivabra-
dine on top of target dose β-blockade.
METHODS
Overview
A Markov model has been used to estimate the costs and clinical
outcomes for two cohorts of patients with HF treated with
either ivabradine or standard care in line with the EU labelled
indication (heart rate ≥75 bpm).
HF is a chronic, progressive disease requiring lifelong therapy
and consequently the cost effectiveness analysis considers a life-
time time horizon, although alternative time horizons, including
an analysis which modelled costs and outcomes only for the
SHIfT trial follow-up period, have been considered in scenario
analyses. An annual discount rate of 3.5% has been applied to
costs and outcomes consistent with the National Institute for
Health and Care Excellence (NICE) recommendations.9 The
cost effectiveness of ivabradine is expressed in terms of the
incremental cost per quality adjusted life year (QALY) gained,
and the analysis has been taken from a UK National Health
Service (NHS) perspective. In order to determine whether ivab-
radine represented value for money, the incremental cost effect-
iveness ratio (ICER) was compared with the NICE cost
effectiveness threshold range of £20 000 to £30 000 per QALY.9
A summary of key model assumptions may be found in table 1.
Mortality and hospitalisation
The cost-effectiveness analysis captures the monthly risk of clinical
events (CV mortality, hospitalisation) using risk equations devel-
oped from SHIfT individual patient data (n=6505). These equa-
tions have been designed to predict outcomes according to the
treatment received and patients’ baseline characteristics including
heart rate. The treatment effect of ivabradine is assumed to be
multiplicative to the underlying risk of these events which has
been based on the data from standard care patients in SHIfT. The
change in efﬁcacy of ivabradine associated with baseline heart rate,
identiﬁed in previous clinical analyses,7 is captured in the risk
equations using a treatment interaction term (treatment×baseline
heart rate). The risk equations consequently allow costs and out-
comes to be predicted for the subgroup of patients with a heart
rate ≥75 bpm, consistent with the European licence indication.
This approach was taken in preference to developing risk equa-
tions based solely on individual patient data from subjects who
met the European licence criteria (baseline heart rate ≥75 bpm
(n=4154)) in order to avoid breaking randomisation and reducing
the predictive power of the risk equations due to the smaller
sample size.
The risk of non-CV mortality has been estimated using age
and sex adjusted UK national life table data with CV mortality
removed.10
NYHA class
The most commonly used classiﬁcation of HF severity is the
NYHA classiﬁcation of functional capacity which assigns
patients to one of four classes depending on patient symp-
toms.11 In each monthly cycle, the patients who remained alive
were distributed into one of the four NYHA classes using a risk
equation developed from SHIfT individual patient data. NYHA
class has been captured in the cost effectiveness analysis primar-
ily to determine the potential quality of life of patients over
time, since NYHA class was found to strongly predict patients’
quality of life. In the post-trial period the proportion of patients
in each NYHA class is assumed to remain ﬁxed (although in
absolute terms numbers in each category vary according to sur-
vival estimates). This approach was taken because an extrapola-
tion based on SHIfT data predicted that the proportion of
patients with minimal or mild symptoms would increase over
time, consistent with trends in SHIfT observed data, which for
the long-term were not considered clinically plausible.
Table 1 Key model assumptions
Parameter description Base case value
Model structure Two state Markov
cohort model
Modelled cycle length 1 month
Time horizon Lifetime
Costs and effects discount rate per annum 3.50%
Parametric survival model CV mortality Gompertz
Extrapolation CV mortality post trial Gompertz
Regression model hospitalisation Poisson
Regression model NYHA class Generalised ordered
logistic
Regression model QoL Multilevel model
Drug costs per month (£)
Standard care average cost per month 9.54
Ivabradine average cost per month 42.10
Other therapy related costs (£)
ECG unit cost 31.28 (12.01–44.30)
CV specialist visit unit cost 118.81 (89.48–138.97)
Hospitalisations cost per event ( £)
HF diagnosis (general ward) 2307.98
HF diagnosis (cardiac ward) 3295.12
Other CV diagnosis (general ward) 1942.44
Other CV diagnosis (cardiac ward) 1729.60
Non-CV diagnosis (general ward) 2643.56
Admission type given hospitalisation
Proportion of hospitalised patients admitted in
cardiac specialist ward versus general ward
50% (40–60%)
Other resource use
Ongoing HF management costs per month 26.77
Regression equations reported in online supplementary technical appendix.
Ivabradine average dose=6.7794 mg, British National Formulary list price £40.17 per
pack.
HF hospitalisation weighted average of HRG (Health Resource Group) codes: EB03H–
EB03I.
Cardiovascular hospitalisation weighted average HRG codes: EA03Z–EB10Z.
All-cause hospitalisation HRG weighted average codes AA02Z–WA23Y.
CV, cardiovascular; HF, heart failure; NYHA, New York Heart Association; QoL,
quality of life.
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Patients’ quality of life
The SHIfT patient reported outcomes substudy collected quality
of life (QoL) data using the EuroQoL (EQ-5D) questionnaire,
which was administered to patients in countries with a validated
questionnaire (n=5313). The EQ-5D is a generic instrument
designed to capture patient reported outcomes across ﬁve health
domains (self-care, mobility, usual activities, pain/discomfort,
anxiety/depression).12 QoL weights (utility values) may be
derived from the EQ-5D using country-speciﬁc values of differ-
ent health statuses; UK values were used in this study regardless
of the country of origin of the QoL data. Utility values typically
measure patient QoL on a scale, where 0 represents death and 1
represents full health, although negative values are feasible.13
Measurements from the same individual are much more likely
to be correlated than estimates from different individuals and it
is important to take into account such correlation when analys-
ing data with repeated measures to increase precision and avoid
bias. EQ-5D data have been analysed using multilevel modelling,
a regression technique appropriate for repeated observations
across individuals. The regression equation was designed to
predict patient utility according to treatment allocation, baseline
characteristics, NYHA class (time varying) and a hospitalisation
episode.
Resource use and costs
The cost per month for ivabradine therapy (£42.10 per month)
was estimated using British National Formulary (BNF) list prices
(5 mg/7.5 mg=£0.72 per tablet, 2.5 mg (half a 5 mg tablet=
£0.36)) multiplied by the distribution of patients taking each
dose in SHIfT (approximately 7% 2.5 mg, and 93% 5 mg or
7 mg). An additional one-off titration visit and ECG has been
included as an administration cost for ivabradine patients. It was
assumed that, once titrated, patients would be monitored at
routine clinical assessments, hence further ongoing administra-
tion costs were not included for ivabradine.14 Standard therapy
use (£9.54 per month) was also estimated, using BNF list prices
and the proportion of patients treated with each therapy in
SHIfT (β-blockers (89%), ACE inhibitors and/or angiotensin
receptor blockers (ARBs) (91%), aldosterone antagonists (60%)
and diuretics (83%)). The analysis includes costs for hospitalisa-
tions by admission type (HF, other CV and non-CV) estimated
from UK NHS data.14 Unit costs were reported for a 2011 cost
year, inﬂation-adjusted where necessary using the health compo-
nent of the UK consumer price index.15 Resource use quantities
and unit costs are summarised in table 1.
Sensitivity analysis
A series of one-way sensitivity analyses on parameter values and
structural assumptions have been undertaken to test the robust-
ness of model results to changes in individual model parameters
while remaining assumptions were held constant. NICE recom-
mends that a range of sensitivity analyses should be undertaken
to reﬂect alternative assumptions for the treatment effect for the
intervention of interest, particularly regarding the modelled
beneﬁt in the post-trial period. In our analyses we have explored
the ivabradine treatment effect using a range of sensitivity ana-
lyses. These include variation of ivabradine’s treatment effect
within 95% CIs (CV mortality, hospitalisation and QoL), vari-
ation in the duration of the effect (gradual reduction until no
further beneﬁt of therapy is assumed over a 5-year and a
10-year range while assuming lifelong costs) and restricting the
ivabradine treatment effect to HF mortality and HF
hospitalisation end points only (rather than to the broader CV
mortality and all-cause hospitalisation end point).
Other sensitivity analyses for mortality included the use of
alternative distributions (exponential and Weibull) for the para-
metric survival analysis and the use of alternative external data
to predict mortality in the post-trial period.16 17 Sensitivity ana-
lyses conducted on the hospitalisation end point included doub-
ling and halving the rate of hospitalisation and applying
alternative UK data for hospitalisation length of stay (National
HF Audit and Hospital Episode Statistics data18 19). Quality of
life estimates were explored using alternative utility estimates
from external sources.20 The distribution of patients in each
NYHA class in the post-trial period was explored using a mod-
elled scenario in which patients’ symptoms were assumed to
deteriorate over time (5% of patients were redistributed each
year into NYHA classes associated with more severe HF
symptoms).
Probabilistic sensitivity analysis has been used to assess overall
parameter uncertainty in the model. In this analysis point esti-
mates for each parameter have been replaced with values
sampled from statistical distributions and the ICER has been
recalculated using the new resampled values.21 This process has
been repeated 1000 times to predict the likelihood that ivabra-
dine would be cost-effective at different cost effectiveness
thresholds (the value the decision maker is willing to pay for
each additional QALY).
Subgroup analyses
Subgroup analyses have been performed for subgroup popula-
tions identiﬁed from the clinical study protocol. These included
age (< or ≥75 years old); HF duration (categoried by quartile
cut points); NYHA class; LVEF (categoried by quartile cut
points); prior ischaemia; prior diabetes and β-blocker use.
RESULTS
Base case analysis
A parametric model based on a Gompertz distribution was
established as the best ﬁt of the observed data based on statis-
tical evidence (Akaike and Bayesian information), a visual
review of Kaplan-Meier survival plots versus predicted curves
and the plausibility of predicted survival in the extrapolated,
post-trial period (see online supplementary technical appendix).
The parametric survival analysis predicted that mean survival
for ivabradine patients with a heart rate ≥75 bpm would be
5.61 years compared with 5.86 years for standard care patients.
Ivabradine was expected to improve patient survival duration by
0.25 years (approximately 3.0 months) compared with standard
care. Our analysis suggests that, over 1 year, approximately 225
patients would need to be treated to prevent one HF death.
Quality of life scores for the base case analysis ranged from
0.82 to 0.46 for standard care patients and from 0.84 to 0.47
for ivabradine patients (based on NYHA classes I–IV, and no
hospitalisation event). QoL increased, on average, by 0.014 due
to ivabradine therapy itself. However, hospitalisations were asso-
ciated with a substantial temporary QoL loss, which varied
according to NYHA class (−0.04 to −0.29; NYHA I–IV).
Ivabradine therapy was also associated with a reduction in hos-
pitalisations and hence also avoided the potential QoL loss asso-
ciated with these events, see table 2. Overall, in a lifetime
analysis, ivabradine plus standard care was associated with a
gain of 0.28 QALYs (approximately 3.4 quality adjusted life
months) versus standard care alone.
The model predicted that, over a lifetime, ivabradine would
be £2376 more expensive per patient compared with standard
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care alone. The additional drug therapy and follow-up costs
(£3341 per patient) were offset by an important reduction in
expected hospitalisation costs (£965 per patient). In HF, with a
heart rate ≥75 bpm, ivabradine would be expected to reduce
the rate of HF hospitalisation from approximately 18 hospitali-
sations per 1000 patient months (standard care) to 13 hospitali-
sations per 1000 patient months (ivabradine plus standard care);
20 patients would need to be treated to prevent one HF
hospitalisation.
The incremental cost per additional QALY for ivabradine plus
standard care versus standard care has been estimated as £8498
for heart rate ≥75 bpm and £13 764 for heart rate ≥70 bpm.
Subgroup analyses
The cost per QALY increased by 20% in patients on target dose
β-blocker therapy due to their lower risk of mortality and hospi-
talisation and a slightly lower heart rate compared with patients
not on target dose therapy. Despite this increase, ivabradine
remains cost-effective at existing NICE cost effectiveness thresh-
old values. The ICER for patients on target dose β-blocker
therapy is estimated as £10 374 per QALY (heart rate ≥75 bpm)
and £16 578 per QALY (heart rate ≥70 bpm).
Deterministic sensitivity analysis
The Tornado diagram in ﬁgure 1 shows the effect on the esti-
mated ICER if one model assumption is altered while other
assumptions/parameter values remain at base case values. The
ICER remains below £20 000 in virtually all scenarios. The
ICER was sensitive to changes in the treatment effects of ivabra-
dine at the upper bound 95% CI for CV mortality (HR 0.80 to
1.03). However, the risk equations were developed using data
from the total SHIfT population (heart rate ≥70 bpm), there-
fore, this scenario analysis overestimates the upper bound HR
and ICER estimate for the licensed indication (heart rate
≥75 bpm). A scenario analysis which modelled costs and out-
comes only for the SHIfT trial follow-up period resulted in an
ICER of £15 175. This estimate was less favourable than the
base case estimate because the short time horizon did not take
into account long-term beneﬁts associated with ivabradine.
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis indicates that, using a cost effect-
iveness threshold of £20 000 per QALY, ivabradine plus
standard care has a greater than 0.95 probability of being cost-
effective versus standard care alone in a population with a heart
rate ≥75 bpm (ﬁgure 2), and over 0.70 probability in a popula-
tion ≥70 bpm.
DISCUSSION
The cost effectiveness analysis suggests that ivabradine plus
standard care has a high probability of being cost-effective
versus standard care alone in patients with HF who are in sinus
rhythm with left ventricular systolic dysfunction and have a
baseline heart rate either ≥75 bpm or ≥70 bpm. The cost effect-
iveness of ivabradine is driven by important reductions in HF
mortality and hospitalisation and associated costs of care as well
as improvements in QoL.
Probabilistic sensitivity analyses suggest that, at the current
lower bound NICE cost effectiveness threshold range, ivabradine
plus standard care therapy has a 0.95 probability of being cost-
effective versus standard care alone in a population consistent with
the European licensed indication (heart rate ≥75 bpm), and over a
0.70 probability in the entire SHIfT study population (heart rate
≥70 bpm). The cost effectiveness results were robust to a range of
sensitivity analyses that tested alternative assumptions for param-
eter values and model structure. Our analyses also indicated that
ivabradine would be expected to remain effective in a range of
patient subgroups including those on target dose β-blockade. A
separate budget impact analysis undertaken by NICE indicated
that the total budget impact of ivabradine in the UK would be
expected to be approximately £4400 per 100 000 people.22
The cost effectiveness analysis has been developed using indi-
vidual patient data from a pivotal, large scale randomised con-
trolled trial SHIfT. Model results have been shown to be robust
and calibrate well against observed patient data.
It is acknowledged that that the cost effectiveness result for
patients on target dose β-blockade may appear to contradict
simple univariable analyses based on SHIfT data that indicated
that ivabradine was not associated with a statistically signiﬁcant
treatment effect on either mortality or the rate of hospitalisation
in these patients. SHIfT patients on target dose β-blockade were
found to be generally healthier and at a low risk of mortality
and hospitalisation. Furthermore, there were only 15 HF deaths
(standard care) and 10 HF deaths with ivabradine plus standard
care in patients on target dose therapy with heart rate ≥75 bpm
(n=938). While the HR of patients on target dose therapy (HR:
0.68) was close to the HR observed in the base case population
(HR: 0.62), the underlying clinical event rate was insufﬁcient to
provide statistical signiﬁcance. It is also noted that the baseline
characteristics of patients on target dose β-blockade in the ivab-
radine treatment group differed from those patients on target
dose therapy in the standard care treatment group. In isolation,
univariable analyses may consequently provide a misleading
picture of the ivabradine treatment effect given a low underlying
clinical event rate, small sample size in this subgroup and no
correction for clinical differences at baseline between patients. A
strength of this study is that it is based on multivariable risk
equations which take into account the change in efﬁcacy of ivab-
radine by baseline heart rate and adjust for differences in key
prognostic risk factors. Our analyses indicated that there was no
evidence that the treatment effect of ivabradine was altered by
β-blocker use, ischaemia or age once differences in baseline
heart rate had been taken into account (p>0.05). This sug-
gested that, if patient heart rate remained high despite target
β-blocker dose, ivabradine has a beneﬁcial effect. Although the
underlying clinical event rate in patients on target dose
β-blocker therapy may be low, ivabradine is nevertheless
Table 2 Utility values predicted for SHIfT population heart rate
≥75 bpm
Description Utility value
No hospitalisation
NYHA I 0.82
NYHA II 0.74
NYHA III 0.64
NYHA IV 0.46
Hospitalisation
NYHA I −0.04
NYHA II −0.07
NYHA III −0.10
NYHA IV −0.29
Ivabradine 0.01
Regression equation for quality of life estimates reported in online supplementary
technical appendix.
Utility values estimated using EQ-5D data; UK tariff values.
NYHA, New York Heart Association.
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expected to reduce mortality and hospitalisations in such
patients relative to standard care.
These analyses were designed to derive the most likely esti-
mate of effect for ivabradine in speciﬁc patient subgroups
including those patients on target dose β-blocker therapy based
on available evidence from SHIfT. An alternative approach to
determining the clinical effect of ivabradine on top of target
dose β-blockade would be to conduct a randomised trial in this
population. However, such a trial would have to be large, as
those patients who tolerate target dose β-blockade in SHIfT
appeared to be the healthiest, lowest-risk patients hence the
underlying event rate in these patients is likely to be low.
In summary, from a UK NHS perspective, ivabradine in combin-
ation with optimised standard care therapy, including β-blockade,
Table 3 Base-case results in patients with heart rate ≥75 bpm and ≥70 bpm
Population Technologies
Total
costs (£)
Total
LYs
Total
QALYs
Incremental
costs (£)
Incremental
LYs
Incremental
QALYs
ICER (£)
incremental LYs
ICER (£)
incremental
QALY
Heart rate
≥75 bpm
Standard care 9446 5.61 3.99 – – – – –
Ivabradine plus std
care
11 822 5.86 4.27 2376 0.25 0.28 9363 8498
Heart rate
≥70 bpm
Standard care 9312 5.89 4.23 – – – –
Ivabradine plus
standard care
11 796 6.03 4.41 2484 0.14 0.18 17 875 13 764
ICER, incremental cost effectiveness ratio; LY, life years; QALY, quality adjusted life years.
Figure 1 One way sensitivity analyses for patients with heart failure (HF), heart rate ≥75 bpm (£).
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has a high probability of being cost-effective versus standard care
alone in patients with HF, who are in sinus rhythm with left ven-
tricular systolic dysfunction and a baseline heart rate either
≥75 bpm or ≥70 bpm. In support of this, the single technology
appraisal of ivabradine by NICE concluded that this analysis was
robust and unlikely to overestimate the cost effectiveness, leading
to a recommendation that patients in England and Wales should
have access to this therapy if indicated. 9
Key messages
What is already known about this subject?
Ivabradine, a speciﬁc heart rate lowering therapy, has been
shown in a randomised placebo-controlled study, Systolic HF
Treatment with the If Inhibitor Ivabradine Trial (SHIfT), to
signiﬁcantly reduce the composite end point of cardiovascular
death and hospitalisation for worsening heart failure (HF) in
patients with systolic HF who are in sinus rhythm and with a
heart rate ≥70 bpm, when added to optimised medical therapy.
What does this study add?
We assessed the cost effectiveness of ivabradine, from a UK
National Health Service (NHS) perspective, based on the results
of SHIfT. The incremental cost per additional quality adjusted life
year (QALY) for ivabradine plus standard care versus standard
care has been estimated as £8498 for heart rate ≥75 bpm and
£13 764 for heart rate ≥70 bpm. Ivabradine is expected to have
a 95% chance of being cost-effective in the EU licensed
population using the current National Institute of Health and
Care Excellence (NICE) cost effectiveness threshold of £20 000
per QALY.
How might this impact on clinical practice?
These results should encourage clinicians to prescribe ivabradine
to appropriate patients, as it has a clinical effect that represents
good value for money when added to optimised medical
therapy.
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